-
公开(公告)号：US20140302511A1
公开(公告)日：2014-10-09
申请号：US14354517
申请日：2012-10-26
发明人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Takeshi Watanabe , Koichi Matsubara , Osamu Natori , Atsuhiko Kato , Masami Suzuki
IPC分类号： C07K16/18 , G01N33/574 , C12Q1/68
CPC分类号： C07K16/28 , A61K31/4745 , A61K39/0011 , A61K39/39558 , A61K2039/55566 , C07K14/51 , C07K16/18 , C07K16/3046 , C07K2317/41 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C12Q1/686 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/574 , G01N33/57419 , G01N33/57492 , G01N2333/726 , G01N2800/52
摘要： An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective of the present invention is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.
摘要翻译： 本发明的目的是获得可以使用细胞表面标志物Lgr5表征的两种类型的实质均匀的癌症干细胞群体，并且通过使用针对这些癌症干细胞特异性表达的细胞膜分子的抗体提供癌症治疗剂 识别所述细胞膜分子。 本发明的另一个目的是提供使用针对癌干细胞特异性表达的细胞膜分子的抗体，用于检测癌症干细胞的试剂，以及用于诊断和分选癌症患者的方法。 本发明人发现可以大量获得高纯度大肠癌干细胞（CSC），并且通过Lgr5表达鉴定了可以区分的大肠CSCs的两种状况。 此外，本发明人发现，针对在所述癌干细胞中特异性表达的细胞膜分子的抗体可以损伤所述细胞。
-
公开(公告)号：US20200325222A1
公开(公告)日：2020-10-15
申请号：US16913341
申请日：2020-06-26
发明人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Takeshi Watanabe , Koichi Matsubara , Osamu Natori , Atsuhiko Kato , Masami Suzuki
IPC分类号： C07K16/28 , C07K16/30 , C07K14/51 , G01N33/574 , A61K39/00 , C12Q1/6886 , C07K16/18 , C12Q1/686 , A61K31/4745 , A61K39/395
摘要： An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.
-
公开(公告)号：US11858987B2
公开(公告)日：2024-01-02
申请号：US16913341
申请日：2020-06-26
发明人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Takeshi Watanabe , Koichi Matsubara , Osamu Natori , Atsuhiko Kato , Masami Suzuki
IPC分类号： C07K16/28 , C07K16/30 , C07K14/51 , G01N33/574 , C12Q1/6886 , A61K39/00 , C07K16/18 , C12Q1/686 , A61K31/4745 , A61K39/395
CPC分类号： C07K16/28 , A61K31/4745 , A61K39/001102 , A61K39/39558 , C07K14/51 , C07K16/18 , C07K16/3046 , C12Q1/686 , C12Q1/6886 , G01N33/574 , G01N33/57419 , G01N33/57492 , A61K2039/55566 , C07K2317/41 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C12Q2600/106 , C12Q2600/158 , G01N2333/726 , G01N2800/52
摘要： An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.
-
公开(公告)号：US10934351B2
公开(公告)日：2021-03-02
申请号：US15042548
申请日：2016-02-12
发明人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Takeshi Watanabe , Koichi Matsubara , Osamu Natori , Atsuhiko Kato , Masami Suzuki
IPC分类号： C07K16/28 , C07K16/30 , C07K14/51 , A61K39/00 , C07K16/18 , A61K31/4745 , A61K39/395 , G01N33/574 , C12Q1/6886 , C12Q1/686
摘要： An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.
-
公开(公告)号：US20160159904A1
公开(公告)日：2016-06-09
申请号：US15042548
申请日：2016-02-12
发明人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Takeshi Watanabe , Koichi Matsubara , Osamu Natori , Atsuhiko Kato , Masami Suzuki
IPC分类号： C07K16/28 , A61K31/4745 , A61K39/395 , C07K16/30
CPC分类号： C07K16/28 , A61K31/4745 , A61K39/0011 , A61K39/39558 , A61K2039/55566 , C07K14/51 , C07K16/18 , C07K16/3046 , C07K2317/41 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C12Q1/686 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/574 , G01N33/57419 , G01N33/57492 , G01N2333/726 , G01N2800/52
摘要： An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.
摘要翻译： 本发明的目的是获得可以使用细胞表面标志物Lgr5表征的两种类型的实质均匀的癌症干细胞群体，并且通过使用针对这些癌症干细胞特异性表达的细胞膜分子的抗体提供癌症治疗剂 识别所述细胞膜分子。 另一个目的是提供使用针对癌干细胞特异性表达的细胞膜分子的抗体，用于检测癌症干细胞的试剂，以及用于诊断和分选癌症患者的方法。 本发明人发现可以大量获得高纯度大肠癌干细胞（CSC），并且通过Lgr5表达鉴定了可以区分的大肠CSCs的两种状况。 此外，本发明人发现，针对在所述癌干细胞中特异性表达的细胞膜分子的抗体可以损伤所述细胞。
-
-
-
-
搜索结果
5 条记录 (耗时 0.025 秒)
